IDS Serum CrossLaps® (CTX-I) ELISA (RUO)

Last updated: 31st July, 2019

The Serum CrossLaps® (CTX-I) ELISA assay is an enzyme immunological test for the quantification of degradation products of C-terminal telopeptides of Type I collagen in human serum and plasma.

It is intended for in-vitro diagnostic use as an indication of human bone resorption and may be used as an aid in:

Monitoring bone resorption changes of:

a) Anti-resorptive therapies in postmenopausal women:

  • Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
  • Bisphosphonate therapies

b) Anti-resorptive therapies in individuals diagnosed with osteopaenia:

  • Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs
  • Bisphosphonate therapies

Predicting skeletal response (Bone Mineral Density) in postmenopausal women undergoing anti-resorptive therapies:

a) Hormone Replacement Therapies (HRT) with hormones and hormone-like drugs

b) Bisphosphonate therapies

Unique Features

  • Management of Postmenopausal Osteoporosis
  • Prediction of long-term skeletal response to anti-resorptive therapies, e.g. HRT, bisphosphonates
  • Increase in patient motivation and compliance
  • Assessment of Bone Resorption in Patients
  • With metabolic bone disease, e.g. hyperparathyroidism, Paget´s disease, osteodystrophy
  • Receiving prolonged glucocorticoid therapy
  • A reference marker for osteoporosis management as indicated by IOF, IFCC and NBHA
  • Easy to perform – one step incubation
  • Excellent correlation with automated methods

View IDS Serum Crosslaps ELISA (RUO) Flyer

Download Now >

Find out more about IDS specialised EIA and RIA Immunoassays for research

Click Here >

Contact us for a quote

Contact Us Now >
Go BackGo Back
Top